Bionano Genomics has incrementally expanded its installed base of optical genome mapping systems and sustained stable consumable sales, underpinned by a reagent rental model fostering recurring revenues. However, overall revenue contracted year-over-year for 2025 while operating losses narrowed significantly from prior years amid restructuring efforts. The company faces substantial liquidity risks, with cash reserves insufficient beyond early 2027 under current plans and ongoing operational deficits. Bionano’s competitive moat is built on proprietary OGM technology and integrated software but scaling adoption in a competitive genomics market and navigating capital needs remain material challenges.